Basic Information
Lysodren
Regulatory Information
EMEA/H/C/000521
Authorised
April 28, 2004
23
August 21, 2024
Company Information
France
25 Boulevard Romain Rolland 92120 Montrouge
ESTEVE RD FRANCE SAS
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. The effect of Lysodren on non-functional adrenal cortical carcinoma is not established.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Lysodren. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Lysodren.